Trial Profile
Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- Acronyms EDSPD
- 22 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 02 Feb 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 12 Jun 2020 Planned End Date changed from 1 May 2022 to 1 Dec 2022.